Daxor awarded new patent for remote monitoring of blood volume

Daxor announces that Daxor was recently granted a patent for a system to provide remote blood volume monitoring after initial testing with Daxor BVA-100 diagnostic. This U.S. patent number adds to our existing portfolio that includes more than a dozen issued and pending-review patents. The recently issued patent provides remote blood volume monitoring through various methods including wearable devices such as smartwatches for a wide variety of medical conditions for which volume assessment is recommended. This proprietary technology will help ensure ongoing care is optimized based on the patient’s evolving blood volume status. “Daxor has a robust research and development program focused on innovation and next-generation technologies, including approaches to blood volume optimization that rely on leveraging smart algorithms, computer-assisted clinical decision support, and novel hardware. These efforts are supported by funding we have received from the National Institute of Health and United States Department of Defense and are part of our strategy of adding significant intellectual property assets to the company to fuel future product development,” said Michael Feldschuh, Chief Executive Officer of Daxor.